Regeneron Pharmaceuticals EBITDA 2010-2024 | REGN

Regeneron Pharmaceuticals EBITDA for the quarter ending December 31, 2024 was $1.117B, a 2.83% increase year-over-year.

  • Regeneron Pharmaceuticals 2024 EBITDA was 4.474B, a 0.12% increase from 2023.
  • Regeneron Pharmaceuticals 2023 EBITDA was 4.468B, a 12.05% decline from 2022.
  • Regeneron Pharmaceuticals 2022 EBITDA was 5.08B, a 44.98% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Regeneron Pharmaceuticals EBITDA 2010-2024 | REGN

  • Regeneron Pharmaceuticals 2024 EBITDA was 4.474B, a 0.12% increase from 2023.
  • Regeneron Pharmaceuticals 2023 EBITDA was 4.468B, a 12.05% decline from 2022.
  • Regeneron Pharmaceuticals 2022 EBITDA was 5.08B, a 44.98% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.